

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S)	S. Denmeade, et al.	EXAMINER:	S. Liu
U.S.S.N.:	09/627,600	GROUP:	1653
FILED (U.S.):	July 28, 2000	Conf. No.	3631
FOR:	ACTIVATION OF PEPTIDE PRODRUGS BY (HK2)		

BOX SEQUENCE

Commissioner for Patents
Washington, D.C. 20231

Sir/Madam:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

The following is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed July 3, 2002, in the above-referenced application.

Enclosed herewith for filing in the subject application are the following:

1. Paper Copy of Sequence Listing previously submitted;
2. New Computer Readable Form (CRF) of Sequence Listing;
3. Copy of Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acids Sequence Disclosures;
4. Copy of Error Report indicating unreadable disc;
5. Amendment directing entry of Paper Copy of Sequence Listing into specification [included in this paper];
6. Statement Accompanying Submission Of Sequence Listing Under 37 C.F.R. § 1.821(g) (included in this paper);
7. Associate Power of Attorney; and
8. Change of Correspondence Address.

Attorney Docket No. 57109 (71699)
U.S.S.N. 09/627,600
Filed (U.S.): July 28, 2000
Page 2 of 2

AMENDMENT DIRECTING ENTRY OF SEQUENCE LISTING

At the last page of the specification, please enter the attached paper copy of the Sequence Listing (25 pages) and number the pages as appropriate.

STATEMENT ACCOMPANYING SUBMISSION OF SEQUENCE LISTING

Provided herewith is a Paper Copy of a Sequence Listing for the nucleotide and/or amino acid sequence(s) in this application. Each Sequence has been assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823. An amendment directing entry of the Paper Copy of the Sequence Listing into the specification is provided above.

Applicants further provide a Computer Readable Form (CRF) corresponding to the Paper Copy of the Sequence Listing provided herewith. Pursuant to 37 C.F.R. § 1.821(g), Applicants' agent hereby states that the CRF corresponds exactly to the Paper Copy of the Sequence Listing provided herewith. Applicants' agent further hereby states that the contents of the Paper Copy of the Sequence Listing and CRF do not go beyond the disclosure in the Application as filed and do not introduce new matter.

If for any reason, the fee paid is inadequate or credit is owed for any excess fee paid, you are hereby authorized and requested to charge Deposit Account No. **04-1105**.

Date: July 18, 2002

Respectfully submitted,

Dianne M. Rees
Dianne M. Rees, Ph.D.
(Reg. No. 45,281)
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209

Telephone: 617-439-4444
Customer No. 21874
BOS2_307161.1

Mailing Date: 7/18/02

Client: 71299

Inventors: Denmeade, et al

Serial No.: 09/627,400

Filing Date: 7/28/00

Attorney/Sec: Dym/hmt

Docket No.: 57109

Patent No.:

Grant Date:

The dating stamp of the Patent and Trademark Office hereon will be taken as the date of filing of:

Response to Notice of Missing Requirements;
copy of Paper Sequence & disk;
copy of previously filed response 10/19/01
change of Address
associate Power of Attorney

Due Date: 8/3/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Isaacs et al. Art Unit : 1653
Serial No. : 09/627,600 Examiner : H. Robinson
Filed : July 28, 2000
Title : ACTIVATION OF PEPTIDE PRODRUGS BY HK2

BOX SEQUENCE

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated September 21, 2001 (copy enclosed), applicants submit herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, applicants submit an initial Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(f).

Applicants respectfully request entry of the paper copy and computer readable copy of the Sequence Listing filed herewith for the instant application. Furthermore, applicants request entry of the following amendments.

In the specification:

Insert the paper copy of the Sequence Listing filed herewith following the Oath/Declaration.

Replace the paragraph beginning at page 4, line 10, with the following rewritten paragraph:

--Fig. 1 is a portion of the amino acid sequence of Semenogelin I (SEQ ID NOs:1-4) and Semenogelin II (SEQ ID NOs:5-11), showing the cleavage sites for human kallikrein 2.--

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

October 19, 2001
Date of Deposit

Signature Shahreen Mehjabeen

SHAHREEN MEHTABEEN
Typed or Printed Name of Person Signing Certificate

Replace the paragraph beginning at page 5, line 29, with the following rewritten paragraph:

--Some examples of preferred peptides include (Note that the symbol][denotes an hK2 cleavage site):

1. Lys-Arg-Arg][(SEQ ID NO:12)
2. Ser-Arg-Arg][(SEQ ID NO:13)
3. Ala-Arg-Arg][(SEQ ID NO:14)
4. His-Arg-Arg][(SEQ ID NO:15)
5. Gln-Arg-Arg][(SEQ ID NO:16)
6. Ala-Phe-Arg][(SEQ ID NO:17)
7. Ala-Gln-Arg][(SEQ ID NO:18)
8. Ala-Lys-Arg][(SEQ ID NO:19)
9. , Ala-Arg-Lys][(SEQ ID NO:20)
10. Ala-His-Arg][(SEQ ID NO:21)--

Replace the paragraph beginning at page 6, line 12, with the following rewritten paragraph:

--Additional preferred peptides of longer sequence length include:

11. Gln-Lys-Arg-Arg][(SEQ ID NO:22)
12. Lys-Ser-Arg-Arg][(SEQ ID NO:23)
13. Ala-Lys-Arg-Arg][(SEQ ID NO:24)
14. Lys-Lys-Arg-Arg][(SEQ ID NO:25)
15. His-Lys-Arg-Arg][(SEQ ID NO:26)
16. Lys-Ala-Phe-Arg][(SEQ ID NO:27)
17. Lys-Ala-Gln-Arg][(SEQ ID NO:28)
18. Lys-Ala-Lys-Arg][(SEQ ID NO:29)
19. Lys-Ala-Arg-Lys][(SEQ ID NO:30)
20. Lys-Ala-His-Arg][(SEQ ID NO:31)--

Replace the paragraph beginning at page 6, line 24, with the following rewritten paragraph:

--Additional preferred peptides that include an X-1 amino acid are:

21. Lys-Arg-Arg][Leu (SEQ ID NO:32)
22. Ser-Arg-Arg][Leu (SEQ ID NO:33)
23. Ala-Arg-Arg][Leu (SEQ ID NO:34)
24. Ala-Arg-Arg][Ser (SEQ ID NO:35)
25. His-Arg-Arg][Ala (SEQ ID NO:36)
26. Gln-Arg-Arg][Leu (SEQ ID NO:37)
27. Ala-Phe-Arg][Leu (SEQ ID NO:38)
28. Ala-Gln-Arg][Leu (SEQ ID NO:39)
29. , Ala-Lys-Arg][Leu (SEQ ID NO:40)
30. Ala-Arg-Lys][Leu (SEQ ID NO:41)
31. Ala-His-Arg][Leu (SEQ ID NO:42)--

Replace the paragraph beginning at page 7, line 7, with the following rewritten paragraph:

--Preferred peptides of still longer sequence length having X₁ include:

32. His-Ala-Gln-Lys-Arg-Arg][Leu (SEQ ID NO:43)
33. Gly-Gly-Lys-Ser-Arg-Arg][Leu (SEQ ID NO:44)
34. His-Glu-Gln-Lys-Arg-Arg][Leu (SEQ ID NO:45)
35. His-Glu-Ala-Lys-Arg-Arg][Leu (SEQ ID NO:46)
36. Gly-Gly-Gln-Lys-Arg-Arg][Leu (SEQ ID NO:47)
37. His-Glu-Gln-Lys-Arg-Arg][Ala (SEQ ID NO:48)
38. Gly-Gly-Ala-Lys-Arg-Arg][Leu (SEQ ID NO:49)
39. His-Glu-Gln-Lys-Arg-Arg][Ser (SEQ ID NO:50)
40. Gly-Gly-Lys-Lys-Arg-Arg][Leu (SEQ ID NO:51)
41. Gly-Gly-His-Lys-Arg-Arg][Leu (SEQ ID NO:52)--

Replace the paragraph beginning at page 15, line 28, with the following rewritten paragraph:

--Recombinant hK2 was produced and purified as described in Lövgren et al., *Biochem. Biophys. Res. Co.*, 238, 549-555 (1997). Semenogelin I and II were isolated from human semen as described previously in Malm et al., *Eur. J. Biochem.*, 238, 48-53 (1996). The tripeptide aminomethylcoumarin (AMC) substrates Boc-Phe-Ser-Arg-AMC (SEQ ID NO:53), Boc-Gln-Gly-Arg-AMC (SEQ ID NO:54), H-Pro-Phe-Arg-AMC (SEQ ID NO:55), boc-Val-Pro-Arg-AMC (SEQ ID NO:56), H-D-Val-Leu-Lys-AMC (SEQ ID NO:57), Tos-Gly-Pro-Arg-AMC (SEQ ID NO:58), Tos-Gly-Pro-Lys-AMC (SEQ ID NO:59), Z-Leu-Leu-Arg-AMC (SEQ ID NO:60), Z-Val-Val-Arg-AMC (SEQ ID NO:61), Z-Ala-Arg-Arg-AMC (SEQ ID NO:62), and H-Arg-Gln-Arg-Arg-AMC (SEQ ID NO:63) were from Bachem (Bubendorf, Switzerland). The heptapeptide substrates Mu-Ala-Pro-Val-Leu-Ile-Leu-Ser-Arg-AMC (SEQ ID NO:64) and Mu-Val-Pro-Leu-Ile-Gln-Ser-Arg-AMC (SEQ ID NO:65) corresponding to the pro peptides of PSA hK2 were from Enzyme Systems Product (Livermore, CA, USA). ACT was purified from human blood plasma as described in Christensson et al., *Eur. J. Biochem.*, 194, 755-63 (1990). PCI was provided by Prof. Johan Stenflo (Malmö University Hospital, Malmö, Sweden), and SLPI, and PSTI by Prof. Kjell Ohlsson (Malmö University Hospital, Malmö, Sweden). Benzamidine hydrochloride was from Amresco® (Solon, OH, USA), leupeptin and antipain were from ICN Biomedicals (Costa Mesa, CA, USA), Aprotinin was from Sigma (St. Louis, MO, USA), and PPACK from Calbiochem (La Jolla, CA, USA).--

Replace the paragraph beginning at page 18, line 10, with the following rewritten paragraph:

--Substrates ending in either arginine or lysine were tested. The kinetic constants for hydrolysis of the substrates by hK2 are shown in Table 1. The best substrate was the kallikrein substrate Pro-Phe-Arg-AMC (SEQ ID NO:55) having the highest k_{cat} and k_{cat}/K_m values. The cathepsin B substrate Ala-Arg-Arg-AMC (SEQ ID NO:62) was also cleaved quite effectively having a relatively high k_{cat} value and a low K_m resulting in a four times lower k_{cat}/K_m value than that obtained for the kallikrein substrate Pro-Phe-Arg-AMC (SEQ ID NO:55). However, no

hydrolysis of Arg-Gln-Arg-Arg-AMC (SEQ ID NO:63) was detected. HK2 cleaved additionally Val-Pro-Arg-AMC (SEQ ID NO:56), and Leu-Leu-Arg-AMC (SEQ ID NO:60), but with lower efficiency. As with the semenogelins hK2 also here cleaves substrates with Arg at position P1 and preferentially a large residue or another Arg at position P2. None of the substrates with lysine in the C-terminal position were cleaved.--

Replace Table 1 beginning at page 19, line 1, with the following rewritten table:

--Table 1. Substrate Hydrolysis by hK2

Substrates	Km (M)	Kcat (min ⁻¹)	Kcat/km (μM ⁻¹ min ⁻¹)	Activity (%)
Pro Phe Arg-AMC (SEQ ID NO:55)	40	55	1.375	100
Val Pro Arg-AMC (SEQ ID NO:56)	48	1.6	0.034	6
Gly Pro Arg-AMC (SEQ ID NO:58)		NR		
Gly Pro Lys-AMC (SEQ ID NO:59)		NR		
Leu Leu Arg-AMC (SEQ ID NO:60)	71	2.4	0.034	7
Val Val Arg-AMC (SEQ ID NO:61)		NR		
Val Leu Lys-AMC (SEQ ID NO:57)		NR		
Phe Ser Arg-AMC (SEQ ID NO:53)		NR		
Gln Gly Arg-AMC (SEQ ID NO:54)		NR		
Ala Arg Arg-AMC (SEQ ID NO:62)	20	7.2	0.360	33
Arg Gln Arg Arg-AMC (SEQ ID NO:63)		NR		

Replace the paragraph beginning at page 19, line 3, with the following rewritten paragraph:

--The activity listed in Table 1 is the hydrolytic activity of hK2 with 100 μ M substrate in relation to the hydrolytic activity of hK2 with 100 μ M of the tissue kallikrein substrate H-Pro-Phe-Arg-AMC (SEQ ID NO:55). The entry "N.R." means that no reaction was detected.--

Replace the paragraph beginning at page 19, line 8, with the following rewritten paragraph:

--Activity of hK2 (1.6 pmol) was monitored using the substrate H-Pro-Phe-Arg-AMC (SEQ ID NO:55) (90 μ M). Inhibitors, at commonly used concentrations, and hK2 (8.3 nM) were mixed and proteolysis of 90 μ M H-Pro-Phe-Arg-AMC (SEQ ID NO:55) was followed up to 20 minutes, starting directly or 10 minutes after mixing the enzyme with various inhibitors. Inhibition was evaluated by comparison with enzyme-free controls.--

Replace the paragraph beginning at page 22, line 27, with the following rewritten paragraph:

--The progress of the reaction of hK2 (8nM final concentration) with the substrate Pro-Phe-Arg-AMC (SEQ ID NO:55) was monitored at two different substrate concentrations without or with different concentrations of PCI (80, 40 or 16 nM final concentration). The fluorescence measurements were started directly after mixing the enzyme with the inhibitor. The inhibitor of hK2 by PCI could be described by the slow-binding inhibition mechanism presented in Scheme 2, which has been used in analyzing the interaction of PCI with various serine proteases (Hermans et al., *Biochem. J.*, 295, 239-245 (1993), and Hermans et al., *Biochemistry*, 33, 5440-44 (1994)). This mechanism assumes that a reversible complex is formed between the proteinase and serine proteinase inhibitor (serpin). The issues justifying the use of the slow binding inhibition mechanism despite the commonly held view that the seprin-proteinase complex is irreversible has been discussed in more detail by Hermans et al. (1993).--

Replace Table 4 beginning at page 25, line 1, with the following rewritten table:

--Table 4. Hydrolysis of hK2 Substrates

Peptide Sequence								hK2 Hydrolysis Rate (FU/hr/mg)	Serum Hydrolysis Rate FU/hr	
P7	P6	P5	P4	P3	P2	P1	P'1			
G	H	E	Q	K	R	R	L	(SEQ ID NO:66)	5966.31	0.17
G	G	G	K	A	R	R	L	(SEQ ID NO:67)	4784.22	0.03
G	G	G	K	A	H	R	L	(SEQ ID NO:68)	4100.94	0.09
G	P	A	H	Q	R	R	L	(SEQ ID NO:69)	4017.81	0.10
G	S	K	G	H	F	R	L	(SEQ ID NO:70)	3029.27	0.04
G	S	K	G	H	R	R	L	(SEQ ID NO:71)	2649.96	UD
G	K	D	V	S	R	R	L	(SEQ ID NO:72)	2316.12	0.08
G	S	Q	N	Q	R	R	L	(SEQ ID NO:73)	2100.48	0.05
G	S	Y	P	S	R	R	L	(SEQ ID NO:74)	2060.21	0.09
G	S	Y	P	S	S	R	L	(SEQ ID NO:75)	1456.18	0.06
G	H	E	Q	K	G	R	L	(SEQ ID NO:76)	650.80	0.04
G	S	N	T	E	R	R	L	(SEQ ID NO:77)	592.34	UD
G	S	Y	E	E	R	R	L	(SEQ ID NO:78)	324.75	0.04
G	K	D	V	S	G	R	L	(SEQ ID NO:79)	242.91	0.05
G	S	N	T	E	K	R	L	(SEQ ID NO:80)	255.90	0.13
G	S	K	G	H	F	H	L	(SEQ ID NO:81)	171.47	0.10
G	S	Q	N	Q	V	R	L	(SEQ ID NO:82)	193.55	0.03
G	P	L	I	L	S	R	L	(SEQ ID NO:83)	118.21	0.07
G	S	Y	E	E	R	H	L	(SEQ ID NO:84)	42.87	0.09
G	K	D	V	S	G	H	L	(SEQ ID NO:85)	67.55	0.05
G	G	G	K	A	H	H	L	(SEQ ID NO:86)	70.15	0.05
G	S	N	T	E	K	H	L	(SEQ ID NO:87)	80.54	0.03
G	P	A	H	Q	D	R	L	(SEQ ID NO:88)	75.34	0.06
G	H	E	Q	K	G	H	L	(SEQ ID NO:89)	1.30	UD
G	P	A	H	Q	D	H	L	(SEQ ID NO:90)	48.06	0.00
G	S	Y	P	S	S	H	L	(SEQ ID NO:91)	24.68	UD
G	S	Q	N	Q	V	H	L	(SEQ ID NO:92)	32.48	0.03--

Replace Table 5 beginning at page 26, line 1, with the following rewritten table:

--Table 5. Additional hK2 Substrates

Substrate Sequence								hK2 Hydrolysis	Serum Hydrolysis	
P7	P6	P5	P4	P3	P2	P1	P'1	Rate(FU/hr/mg)	Rate FU/hr	
G	H	A	Q	K	R	R	L	(SEQ ID NO:93)	3665.1	0.08
	G	G	K	S	R	R	L	(SEQ ID NO:94)	3439.7	0.03
G	H	E	Q	K	R	R	L	(SEQ ID NO:66)	3366.5	UD
G	H	E	A	K	R	R	L	(SEQ ID NO:95)	3324.1	UD
	G	G	Q	K	R	R	L	(SEQ ID NO:96)	3267.4	0.02
G	H	E	Q	K	R	R	A	(SEQ ID NO:97)	3051.5	0.06
	G	G	A	K	R	R	L	(SEQ ID NO:98)	2773.0	0.02
G	H	E	Q	K	R	R	S	(SEQ ID NO:99)	2638.5	UD
	G	G	K	K	R	R	L	(SEQ ID NO:100)	2583.0	UD
G	G	G	H	K	R	R	L	(SEQ ID NO:101)	2428.4	UD
	G	G	K	A	F	R	L	(SEQ ID NO:102)	2374.2	0.07
	A	E	Q	K	R	R	L	(SEQ ID NO:103)	2325.8	0.10
	G	G	K	A	Q	R	L	(SEQ ID NO:104)	2233.7	0.04
	G	G	K	A	R	R	L	(SEQ ID NO:105)	2171.2	UD
	G	G	K	Q	R	R	L	(SEQ ID NO:106)	2171.2	0.02
	G	G	K	H	R	R	L	(SEQ ID NO:107)	2079.2	UD
	H	E	Q	A	R	R	L	(SEQ ID NO:108)	1956.4	0.14
G	G	G	K	A	K	R	L	(SEQ ID NO:109)	1788.9	0.14
	H	E	Q	K	R	R	dL	(SEQ ID NO:110)	1690.9	0.15
G	G	G	K	A	R	R	S	(SEQ ID NO:111)	1609.5	UD
	G	G	K	A	R	K	L	(SEQ ID NO:112)	1602.4	UD
	H	E	Q	K	R	R	E	(SEQ ID NO:113)	1473.8	UD
	G	G	K	A	H	R	L	(SEQ ID NO:114)	1287.4	0.10
	G	G	K	A	N	R	L	(SEQ ID NO:115)	1113.9	0.01
	G	G	K	A	R	Q	L	(SEQ ID NO:116)	1021.9	0.13
	G	G	K	A	R	H	L	(SEQ ID NO:117)	939.3	UD
	G	G	K	A	R	N	L	(SEQ ID NO:118)	828.4	0.25
G	G	G	K	A	dR	R	L	(SEQ ID NO:119)	494.4	0.06
	G	G	K	A	K	K	L	(SEQ ID NO:120)	77.9	UD
	G	G	K	A	H	K	L	(SEQ ID NO:121)	73.2	UD
	G	G	K	A	R	dR	L	(SEQ ID NO:122)	49.6	UD
	G	G	K	A	dR	dR	L	(SEQ ID NO:123)	16.5	UD--

In the claims:

Amend claims 8, 28, and 29 as follows:

--8. (Amended) The peptide of claim 6, wherein the amino acid sequence is selected from the group consisting of Ala-Gln-Lys-Arg-Arg (SEQ ID NO:124), Gly-Lys-Ser-Arg-Arg (SEQ ID NO:125), Glu-Gln-Lys-Arg-Arg (SEQ ID NO:126), Glu-Ala-Lys-Arg-Arg (SEQ ID NO:127), Gly-Gln-Lys-Arg-Arg (SEQ ID NO:128), Gly-Ala-Lys-Arg-Arg (SEQ ID NO:129), Gly-Lys-Lys-Arg-Arg (SEQ ID NO:130), Gly-His-Lys-Arg-Arg (SEQ ID NO:131), Gly-Lys-Ala-Phe-Arg (SEQ ID NO:132), Glu-Lys-Ala-Gln-Arg (SEQ ID NO:133), and Glu-Lys-Ala-Arg-Arg (SEQ ID NO:134).--

--28. (Amended) The composition of claim 17, wherein the peptide is Gly-Gly-Lys-Ala-Arg-Arg-Leu (SEQ ID NO:135).--

--29. (Amended) The composition of claim 17, wherein the therapeutic drug is a compound belonging to the group of thapsigargins which have been derivatized with a moiety containing a primary amine group, the peptide is Gly-Gly-Lys-Ala-Arg-Arg-Leu (SEQ ID NO:135), and the linker is selected from the group consisting of unsubstituted or alkyl-, aryl-, halo-, alkoxy-, alkenyl-, amido- or amino-substituted $\text{CO}-(\text{CH}=\text{CH})_{n1}-(\text{CH}_2)_{n2}-\text{Ar}-\text{NH}_2$, $\text{CO}-(\text{CH}_2)_{n2}-(\text{CH}=\text{CH})_{n1}-\text{Ar}-\text{NH}_2$, $\text{CO}-(\text{CH}_2)_{n2}-(\text{CH}=\text{CH})_{n1}-\text{CO}-\text{NH}-\text{Ar}-\text{NH}_2$, $\text{CO}-(\text{CH}=\text{CH})_{n1}-(\text{CH}_2)_{n2}-\text{CO}-\text{NH}-\text{Ar}-\text{NH}_2$, $\text{CO}-(\text{CH}_2)_{n3}-\text{NH}_2$, and $\text{CO}-(\text{CH}_2)_{n3}-\text{NH}-\text{CO}-\text{CH}(\text{R}_4)-\text{NH}_2$, wherein $n1$ and $n2$ are from 0 to 5, $n3$ is from 0 to 15, Ar is any substituted or unsubstituted aryl group, attachment of NH_2 to Ar is in a ortho, meta or para position with respect to the remainder of the linker, and R_4 is any naturally occurring amino acid side chain.--

Applicant : Isaacs et al.
Serial No. : 09/627,600
Filed : July 28, 2000
Page : 10

Attorney's Docket No.: 07265-191001 / DM-3575

REMARKS


Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert the paper copy of the Sequence Listing and sequence identifiers in the specification. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: October 19, 2001



George E. Heibel, Ph.D.
Reg. No. 42,648

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

"Version With Markings to Show Changes Made"

In the specification:

Paragraph beginning at page 4, line 10, has been amended as follows:

Fig. 1 is a portion of the amino acid sequence of Semenogelin I (SEQ ID NOs:1-4) and Semenogelin II (SEQ ID NOs:5-11), showing the cleavage sites for human kallikrein 2.

Paragraph beginning at page 5, line 29, has been amended as follows:

Some examples of preferred peptides include (Note that the symbol][denotes an hK2 cleavage site):

1. Lys-Arg-Arg][(SEQ ID NO:12)
2. Ser-Arg-Arg][(SEQ ID NO:13)
3. Ala-Arg-Arg][(SEQ ID NO:14)
4. His-Arg-Arg][(SEQ ID NO:15)
5. Gln-Arg-Arg][(SEQ ID NO:16)
6. Ala-Phe-Arg][(SEQ ID NO:17)
7. Ala-Gln-Arg][(SEQ ID NO:18)
8. Ala-Lys-Arg][(SEQ ID NO:19)
9. Ala-Arg-Lys][(SEQ ID NO:20)
10. Ala-His-Arg][(SEQ ID NO:21)

Paragraph beginning at page 6, line 12, has been amended as follows:

Additional preferred peptides of longer sequence length include:

11. Gln-Lys-Arg-Arg][(SEQ ID NO:22)
12. Lys-Ser-Arg-Arg][(SEQ ID NO:23)
13. Ala-Lys-Arg-Arg][(SEQ ID NO:24)
14. Lys-Lys-Arg-Arg][(SEQ ID NO:25)
15. His-Lys-Arg-Arg][(SEQ ID NO:26)
16. Lys-Ala-Phe-Arg][(SEQ ID NO:27)
17. Lys-Ala-Gln-Arg][(SEQ ID NO:28)

18. Lys-Ala-Lys-Arg][(SEQ ID NO:29)
19. Lys-Ala-Arg-Lys][(SEQ ID NO:30)
20. Lys-Ala-His-Arg][(SEQ ID NO:31)

Paragraph beginning at page 6, line 24, has been amended as follows:

Additional preferred peptides that include an X-1 amino acid are:

21. Lys-Arg-Arg][Leu (SEQ ID NO:32)
22. Ser-Arg-Arg][Leu (SEQ ID NO:33)
23. Ala-Arg-Arg][Leu (SEQ ID NO:34)
24. Ala-Arg-Arg][Ser (SEQ ID NO:35)
25. His-Arg-Arg][Ala (SEQ ID NO:36)
26. Gln-Arg-Arg][Leu (SEQ ID NO:37)
27. , Ala-Phe-Arg][Leu (SEQ ID NO:38)
28. Ala-Gln-Arg][Leu (SEQ ID NO:39)
29. Ala-Lys-Arg][Leu (SEQ ID NO:40)
30. Ala-Arg-Lys][Leu (SEQ ID NO:41)
31. Ala-His-Arg][Leu (SEQ ID NO:42)

Paragraph beginning at page 7, line 7, has been amended as follows:

Preferred peptides of still longer sequence length having X₁ include:

32. His-Ala-Gln-Lys-Arg-Arg][Leu (SEQ ID NO:43)
33. Gly-Gly-Lys-Ser-Arg-Arg][Leu (SEQ ID NO:44)
34. His-Glu-Gln-Lys-Arg-Arg][Leu (SEQ ID NO:45)
35. His-Glu-Ala-Lys-Arg-Arg][Leu (SEQ ID NO:46)
36. Gly-Gly-Gln-Lys-Arg-Arg][Leu (SEQ ID NO:47)
37. His-Glu-Gln-Lys-Arg-Arg][Ala (SEQ ID NO:48)
38. Gly-Gly-Ala-Lys-Arg-Arg][Leu (SEQ ID NO:49)
39. His-Glu-Gln-Lys-Arg-Arg][Ser (SEQ ID NO:50)
40. Gly-Gly-Lys-Lys-Arg-Arg][Leu (SEQ ID NO:51)
41. Gly-Gly-His-Lys-Arg-Arg][Leu (SEQ ID NO:52)

Paragraph beginning at page 15, line 28, has been amended as follows:

Recombinant hK2 was produced and purified as described in Lövgren et al., *Biochem. Biophys. Res. Co.*, 238, 549-555 (1997). Semenogelin I and II were isolated from human semen as described previously in Malm et al., *Eur. J. Biochem.*, 238, 48-53 (1996). The tripeptide aminomethylcoumarin (AMC) substrates [Bos] Boc-Phe-Ser-Arg-AMC (SEQ ID NO:53), Boc-Gln-Gly-Arg-AMC (SEQ ID NO:54), H-Pro-Phe-Arg-AMC (SEQ ID NO:55), boc-Val-Pro-Arg-AMC (SEQ ID NO:56), H-D-Val-Leu-Lys-AMC (SEQ ID NO:57), Tos-Gly-Pro-Arg-AMC (SEQ ID NO:58), Tos-Gly-Pro-Lys-AMC (SEQ ID NO:59), Z-Leu-Ileu-Arg-AMC (SEQ ID NO:60), Z-Val-Val-Arg-AMC (SEQ ID NO:61), Z-Ala-Arg-Arg-AMC (SEQ ID NO:62), and H-Arg-Gln-Arg-Arg-AMC (SEQ ID NO:63) were from Bachem (Bubendorf, Switzerland). The heptapeptide substrates Mu-Ala-Pro-Val-Leu-Ile-Leu-Ser-Arg-AMC (SEQ ID NO:64) and Mu-Val-Pro-Leu-Ile-Gln-Ser-Arg-AMC (SEQ ID NO:65) corresponding to the pro peptides of PSA hK2 were from Enzyme Systems Product (Livermore, CA, USA). ACT was purified from human blood plasma as described in Christensson et al., *Eur. J. Biochem.*, 194, 755-63 (1990). PCI was provided by Prof. Johan Stenflo (Malmö University Hospital, Malmö, Sweden), and SLPI, and PSTI by Prof. Kjell Ohlsson (Malmö University Hospital, Malmö, Sweden). Benzamidine hydrochloride was from Amresco® (Solon, OH, USA), leupeptin and antipain were from ICN Biomedicals (Costa Mesa, CA, USA), Aprotinin was from Sigma (St. Louis, MO, USA), and PPACK from Calbiochem (La Jolla, CA, USA).

Paragraph beginning at page 18, line 10, has been amended as follows:

Substrates ending in either arginine or lysine were tested. The kinetic constants for hydrolysis of the substrates by hK2 are shown in Table 1. The best substrate was the kallikrein substrate Pro-Phe-Arg-AMC (SEQ ID NO:55) having the highest k_{cat} and k_{cat}/K_m values. The cathepsin B substrate Ala-Arg-Arg-AMC (SEQ ID NO:62) was also cleaved quite effectively having a relatively high k_{cat} value and a low K_m resulting in a four times lower k_{cat}/K_m value than that obtained for the kallikrein substrate Pro-Phe-Arg-AMC (SEQ ID NO:55). However, no hydrolysis of Arg-Gln-Arg-Arg-AMC (SEQ ID NO:63) was detected. HK2 cleaved additionally

Val-Pro-Arg-AMC (SEQ ID NO:56), and Leu-Leu-Arg-AMC (SEQ ID NO:60), but with lower efficiency. As with the semenogelins hK2 also here cleaves substrates with Arg at position P1 and preferentially a large residue or another Arg at position P2. None of the substrates with lysine in the C-terminal position were cleaved.

Table 1 beginning at page 19, line 1, has been amended as follows:

Table 1. Substrate Hydrolysis by hK2

Substrates	Km (M)	Kcat (min ⁻¹)	Kcat/km (μM ⁻¹ min ⁻¹)	Activity (%)
Pro Phe Arg-AMC (SEQ ID NO:55)	40	55	1.375	100
Val Pro Arg-AMC (SEQ ID NO:56)	48	1.6	0.034	6
Gly Pro Arg-AMC (SEQ ID NO:58)		NR		
Gly Pro Lys-AMC (SEQ ID NO:59)		NR		
Leu Leu Arg-AMC (SEQ ID NO:60)	71	2.4	0.034	7
Val Val Arg-AMC (SEQ ID NO:61)		NR		
Val Leu Lys-AMC (SEQ ID NO:57)		NR		
Phe Ser Arg-AMC (SEQ ID NO:53)		NR		
Gln Gly Arg-AMC (SEQ ID NO:54)		NR		
Ala Arg Arg-AMC (SEQ ID NO:62)	20	7.2	0.360	33
Arg Gln Arg Arg-AMC (SEQ ID NO:63)		NR		

Paragraph beginning at page 19, line 3, has been amended as follows:

The activity listed in Table 1 is the hydrolytic activity of hK2 with 100 μ M substrate in relation to the hydrolytic activity of hK2 with 100 μ M of the tissue kallikrein substrate H-Pro-Phe-[arg] Arg-AMC (SEQ ID NO:55). The entry "N.R." means that no reaction was detected.

Paragraph beginning at page 19, line 8, has been amended as follows:

Activity of hK2 (1.6 pmol) was monitored using the substrate H-Pro-[Lphe] Phe-[arg] Arg-AMC (SEQ ID NO:55) (90 μ M). Inhibitors, at commonly used concentrations, and hK2 (8.3 nM) were mixed and proteolysis of 90 μ M H-Pro-Phe-Arg-AMC (SEQ ID NO:55) was followed up to 20 minutes, starting directly or 10 minutes after mixing the enzyme with various inhibitors. Inhibition was evaluated by comparison with enzyme-free controls.

Paragraph beginning at page 22, line 27, has been amended as follows:

The progress of the reaction of hK2 (8nM final concentration) with the substrate Pro-Phe-Arg-AMC (SEQ ID NO:55) was monitored at two different substrate concentrations without or with different concentrations of PCI (80, 40 or 16 nM final concentration). The fluorescence measurements were started directly after mixing the enzyme with the inhibitor. The inhibition of hK2 by PCI could be described by the slow-binding inhibition mechanism presented in Scheme 2, which has been used in analyzing the interaction of PCI with various serine proteases (Hermans et al., *Biochem. J.*, 295, 239-245 (1993), and Hermans et al., *Biochemistry*, 33, 5440-44 (1994)). This mechanism assumes that a reversible complex is formed between the proteinase and serine proteinase inhibitor (serpin). The issues justifying the use of the slow binding inhibition mechanism despite the commonly held view that the serpin-proteinase complex is irreversible has been discussed in more detail by Hermans et al. (1993).

Table 4 beginning at page 25, line 1, has been amended as follows:

Table 4. Hydrolysis of hK2 Substrates

Peptide Sequence								hK2 Hydrolysis Rate (FU/hr/mg)	Serum Hydrolysis Rate FU/hr	
P7	P6	P5	P4	P3	P2	P1	P'1			
G	H	E	Q	K	R	R	L	(SEQ ID NO:66)	5966.31	0.17
G	G	G	K	A	R	R	L	(SEQ ID NO:67)	4784.22	0.03
G	G	G	K	A	H	R	L	(SEQ ID NO:68)	4100.94	0.09
G	P	A	H	Q	R	R	L	(SEQ ID NO:69)	4017.81	0.10
G	S	K	G	H	F	R	L	(SEQ ID NO:70)	3029.27	0.04
G	S	K	G	H	R	R	L	(SEQ ID NO:71)	2649.96	UD
G	K	D	V	S	R	R	L	(SEQ ID NO:72)	2316.12	0.08
G	S	Q	N	Q	R	R	L	(SEQ ID NO:73)	2100.48	0.05
G	S	Y	P	S	R	R	L	(SEQ ID NO:74)	2060.21	0.09
G	S	Y	P	S	S	R	L	(SEQ ID NO:75)	1456.18	0.06
G	H	E	Q	K	G	R	L	(SEQ ID NO:76)	650.80	0.04
G	S	N	T	E	R	R	L	(SEQ ID NO:77)	592.34	UD
G	S	Y	E	E	R	R	L	(SEQ ID NO:78)	324.75	0.04
G	K	D	V	S	G	R	L	(SEQ ID NO:79)	242.91	0.05
G	S	N	T	E	K	R	L	(SEQ ID NO:80)	255.90	0.13
G	S	K	G	H	F	H	L	(SEQ ID NO:81)	171.47	0.10
G	S	Q	N	Q	V	R	L	(SEQ ID NO:82)	193.55	0.03
G	P	L	I	L	S	R	L	(SEQ ID NO:83)	118.21	0.07
G	S	Y	E	E	R	H	L	(SEQ ID NO:84)	42.87	0.09
G	K	D	V	S	G	H	L	(SEQ ID NO:85)	67.55	0.05
G	G	G	K	A	H	H	L	(SEQ ID NO:86)	70.15	0.05
G	S	N	T	E	K	H	L	(SEQ ID NO:87)	80.54	0.03
G	P	A	H	Q	D	R	L	(SEQ ID NO:88)	75.34	0.06
G	H	E	Q	K	G	H	L	(SEQ ID NO:89)	1.30	UD
G	P	A	H	Q	D	H	L	(SEQ ID NO:90)	48.06	0.00
G	S	Y	P	S	S	H	L	(SEQ ID NO:91)	24.68	UD
G	S	Q	N	Q	V	H	L	(SEQ ID NO:92)	32.48	0.03

Table 5 beginning at page 26, line 1, has been amended as follows:

Table 5. Additional hK2 Substrates

Substrate Sequence								hK2 Hydrolysis Rate(FU/hr/mg)	Serum Hydrolysis Rate FU/hr	
P7	P6	P5	P4	P3	P2	P1	P'1			
G	H	A	Q	K	R	R	L	(SEQ ID NO:93)	3665.1	0.08
	G	G	K	S	R	R	L	(SEQ ID NO:94)	3439.7	0.03
G	H	E	Q	K	R	R	L	(SEQ ID NO:66)	3366.5	UD
G	H	E	A	K	R	R	L	(SEQ ID NO:95)	3324.1	UD
	G	G	Q	K	R	R	L	(SEQ ID NO:96)	3267.4	0.02
G	H	E	Q	K	R	R	A	(SEQ ID NO:97)	3051.5	0.06
	G	G	A	K	R	R	L	(SEQ ID NO:98)	2773.0	0.02
G	H	E	Q	K	R	R	S	(SEQ ID NO:99)	2638.5	UD
	G	G	K	K	R	R	L	(SEQ ID NO:100)	2583.0	UD
	G	G	H	K	R	R	L	(SEQ ID NO:101)	2428.4	UD
	G	G	K	A	F	R	L	(SEQ ID NO:102)	2374.2	0.07
G	A	E	Q	K	R	R	L	(SEQ ID NO:103)	2325.8	0.10
	G	G	K	A	Q	R	L	(SEQ ID NO:104)	2233.7	0.04
	G	G	K	A	R	R	L	(SEQ ID NO:105)	2171.2	UD
	G	G	K	Q	R	R	L	(SEQ ID NO:106)	2171.2	0.02
	G	G	K	H	R	R	L	(SEQ ID NO:107)	2079.2	UD
G	H	E	Q	A	R	R	L	(SEQ ID NO:108)	1956.4	0.14
	G	G	K	A	K	R	L	(SEQ ID NO:109)	1788.9	0.14
G	H	E	Q	K	R	R	dL	(SEQ ID NO:110)	1690.9	0.15
	G	G	K	A	R	R	S	(SEQ ID NO:111)	1609.5	UD
	G	G	K	A	R	K	L	(SEQ ID NO:112)	1602.4	UD
G	H	E	Q	K	R	R	E	(SEQ ID NO:113)	1473.8	UD
	G	G	K	A	H	R	L	(SEQ ID NO:114)	1287.4	0.10
	G	G	K	A	N	R	L	(SEQ ID NO:115)	1113.9	0.01
	G	G	K	A	R	Q	L	(SEQ ID NO:116)	1021.9	0.13
	G	G	K	A	R	H	L	(SEQ ID NO:117)	939.3	UD
	G	G	K	A	R	N	L	(SEQ ID NO:118)	828.4	0.25
	G	G	K	A	dR	R	L	(SEQ ID NO:119)	494.4	0.06
	G	G	K	A	K	K	L	(SEQ ID NO:120)	77.9	UD
	G	G	K	A	H	K	L	(SEQ ID NO:121)	73.2	UD
	G	G	K	A	R	dR	L	(SEQ ID NO:122)	49.6	UD
	G	G	K	A	dR	dR	L	(SEQ ID NO:123)	16.5	UD

In the claims:

Claims 8, 28, and 29 have been amended as follows:

8. (Amended) The peptide of claim 6, wherein the amino acid sequence is selected from the group consisting of Ala-Gln-Lys-Arg-Arg (SEQ ID NO:124), Gly-Lys-Ser-Arg-Arg (SEQ ID NO:125), Glu-Gln-Lys-Arg-Arg (SEQ ID NO:126), Glu-Ala-Lys-Arg-Arg (SEQ ID NO:127), Gly-Gln-Lys-Arg-Arg (SEQ ID NO:128), Gly-Ala-Lys-Arg-Arg (SEQ ID NO:129), Gly-Lys-Lys-Arg-Arg (SEQ ID NO:130), Gly-His-Lys-Arg-Arg (SEQ ID NO:131), Gly-Lys-Ala-Phe-Arg (SEQ ID NO:132), Glu-Lys-Ala-Gln-Arg (SEQ ID NO:133), and Glu-Lys-Ala-Arg-Arg (SEQ ID NO:134).

28. (Amended) The composition of claim 17, wherein the peptide is Gly-Gly-Lys-Ala-Arg-Arg-Leu (SEQ ID NO:135).

29. (Amended) The composition of claim 17, wherein the therapeutic drug is a compound belonging to the group of thapsigargins which have been derivatized with a moiety containing a primary amine group, the peptide is Gly-Gly-Lys-Ala-Arg-Arg-Leu (SEQ ID NO:135), and the linker is selected from the group consisting of unsubstituted or alkyl-, aryl-, halo-, alkoxy-, alkenyl-, amido- or amino-substituted $\text{CO}-(\text{CH}=\text{CH})_{n1}-(\text{CH}_2)_{n2}-\text{Ar}-\text{NH}_2$, $\text{CO}-(\text{CH}_2)_{n2}-(\text{CH}=\text{CH})_{n1}-\text{Ar}-\text{NH}_2$, $\text{CO}-(\text{CH}_2)_{n2}-(\text{CH}=\text{CH})_{n1}-\text{CO}-\text{NH}-\text{Ar}-\text{NH}_2$, $\text{CO}-(\text{CH}=\text{CH})_{n1}-(\text{CH}_2)_{n2}-\text{CO}-\text{NH}-\text{Ar}-\text{NH}_2$, $\text{CO}-(\text{CH}_2)_{n3}-\text{NH}_2$, and $\text{CO}-(\text{CH}_2)_{n3}-\text{NH}-\text{CO}-\text{CH}(\text{R}_4)-\text{NH}_2$, wherein $n1$ and $n2$ are from 0 to 5, $n3$ is from 0 to 15, Ar is any substituted or unsubstituted aryl group, attachment of NH_2 to Ar is in a ortho, meta or para position with respect to the remainder of the linker, and R_4 is any naturally occurring amino acid side chain.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Isaacs et al.

Art Unit : 1653

Serial No. : 09/627,600

Examiner : H. Robinson

Filed : July 28, 2000

Title : ACTIVATION OF PEPTIDE PRODRUGS BY HK2

BOX SEQUENCE

Commissioner for Patents

Washington, D.C. 20231

VERIFIED STATEMENT UNDER 37 CFR §1.821(f)

I, Jennifer H. Payne, declare that I personally prepared the paper and the computer-readable copy of the Sequence Listing filed herewith for the above-identified application and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: October 18, 2001

Jennifer H. Payne

Fish & Richardson P.C.

225 Franklin Street

Boston, Massachusetts 02110-2804

(617) 542-5070 telephone

(617) 542-8906 facsimile

20331983.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate

SEQUENCE LISTING

<110> Isaacs, John T.
 Denmeade, Samuel R.
 Lilja, Hans

<120> ACTIVATION OF PEPTIDE PRODRUGS BY hK2

<130> 07265-191001

<140> US 09/627,600

<141> 2000-07-28

<150> US 60/146,316

<151> 1999-07-29

<160> 135

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 11

<212> PRT

<213> Homo sapiens

<400> 1

His	Lys	Gly	Gly	Lys	Ala	His	Arg	Gly	Thr	Gln
1				5						10

<210> 2

<211> 11

<212> PRT

<213> Homo sapiens

<400> 2

Ser	Ser	Ser	Tyr	Glu	Glu	Arg	Arg	Leu	His	Tyr
1				5						10

<210> 3

<211> 11

<212> PRT

<213> Homo sapiens

<400> 3

Ser	Ser	Ser	Tyr	Glu	Glu	Arg	Arg	Leu	His	Tyr
1				5						10

<210> 4

<211> 11

<212> PRT

<213> Homo sapiens

<400> 4

Val	Gln	Lys	Asp	Val	Ser	Gln	Arg	Ser	Ile	Tyr
1				5						10

<210> 5
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 5
 Asp Lys Ser Lys Gly His Phe His Met Ile Val
 1 5 10

<210> 6
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 6
 Gln Cys Ser Asn Thr Glu Lys Arg Leu Trp Val
 1 5 10

<210> 7
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 7
 Leu His Pro Ala His Gln Asp Arg Leu Gln His
 1 5 10

<210> 8
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 8
 Lys Ile Ser Tyr Pro Ser Ser Arg Thr Glu Glu
 1 5 10

<210> 9
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 9
 Gly Lys Ser Gln Asn Gln Val Arg Ile Pro Ser
 1 5 10

<210> 10
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 10
 Ser Ser Ser Tyr Glu Glu Arg Arg Leu Asn Tyr
 1 5 10

<210> 11
 <211> 11
 <212> PRT

<213> Homo sapiens

<400> 11

Leu Ser His Glu Gln Lys Gly Arg Tyr Lys Gln
1 5 10

<210> 12

<211> 3

<212> PRT

<213> Homo sapiens

<400> 12

Lys Arg Arg
1

<210> 13

<211> 3

<212> PRT

<213> Homo sapiens

<400> 13

Ser Arg Arg
1

<210> 14

<211> 3

<212> PRT

<213> Homo sapiens

<400> 14

Ala Arg Arg
1

<210> 15

<211> 3

<212> PRT

<213> Homo sapiens

<400> 15

His Arg Arg
1

<210> 16

<211> 3

<212> PRT

<213> Homo sapiens

<400> 16

Gln Arg Arg
1

<210> 17

<211> 3

<212> PRT

<213> Homo sapiens

<400> 17

Ala Phe Arg

1

<210> 18

<211> 3

<212> PRT

<213> Homo sapiens

<400> 18

Ala Gln Arg

1

<210> 19

<211> 3

<212> PRT

<213> Homo sapiens

<400> 19

Ala Lys Arg

1

<210> 20

<211> 3

<212> PRT

<213> Homo sapiens

<400> 20

Ala Arg Lys

1

<210> 21

<211> 3

<212> PRT

<213> Homo sapiens

<400> 21

Ala His Arg

1

<210> 22

<211> 4

<212> PRT

<213> Homo sapiens

<400> 22

Gln Lys Arg Arg

1

<210> 23

<211> 4

<212> PRT

<213> Homo sapiens

<400> 23

Lys Ser Arg Arg

1

<210> 24
<211> 4
<212> PRT
<213> Homo sapiens

<400> 24
Ala Lys Arg Arg
1

<210> 25
<211> 4
<212> PRT
<213> Homo sapiens

<400> 25
Lys Lys Arg Arg
1

<210> 26
<211> 4
<212> PRT
<213> Homo sapiens

<400> 26
His Lys Arg Arg
1

<210> 27
<211> 4
<212> PRT
<213> Homo sapiens

<400> 27
Lys Ala Phe Arg
1

<210> 28
<211> 4
<212> PRT
<213> Homo sapiens

<400> 28
Lys Ala Gln Arg
1

<210> 29
<211> 4
<212> PRT
<213> Homo sapiens

<400> 29
Lys Ala Lys Arg
1

<210> 30
<211> 4
<212> PRT

<213> Homo sapiens

<400> 30

Lys Ala Arg Lys

1

<210> 31

<211> 4

<212> PRT

<213> Homo sapiens

<400> 31

Lys Ala His Arg

1

<210> 32

<211> 4

<212> PRT

<213> Homo sapiens

<400> 32

Lys Arg Arg Leu

1

<210> 33

<211> 4

<212> PRT

<213> Homo sapiens

<400> 33

Ser Arg Arg Leu

1

<210> 34

<211> 4

<212> PRT

<213> Homo sapiens

<400> 34

Ala Arg Arg Leu

1

<210> 35

<211> 4

<212> PRT

<213> Homo sapiens

<400> 35

Ala Arg Arg Ser

1

<210> 36

<211> 4

<212> PRT

<213> Homo sapiens

<400> 36

His Arg Arg Ala
1

<210> 37
<211> 4
<212> PRT
<213> Homo sapiens

<400> 37
Gln Arg Arg Leu
1

<210> 38
<211> 4
<212> PRT
<213> Homo sapiens

<400> 38
Ala Phe Arg Leu
1

<210> 39
<211> 4
<212> PRT
<213> Homo sapiens

<400> 39
Ala Gln Arg Leu
1

<210> 40
<211> 4
<212> PRT
<213> Homo sapiens

<400> 40
Ala Lys Arg Leu
1

<210> 41
<211> 4
<212> PRT
<213> Homo sapiens

<400> 41
Ala Arg Lys Leu
1

<210> 42
<211> 4
<212> PRT
<213> Homo sapiens

<400> 42
Ala His Arg Leu
1

<210> 43
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 43
 His Ala Gln Lys Arg Arg Leu
 1 5

<210> 44
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 44
 Gly Gly Lys Ser Arg Arg Leu
 1 5

<210> 45
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 45
 His Glu Gln Lys Arg Arg Leu
 1 5

<210> 46
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 46
 His Glu Ala Lys Arg Arg Leu
 1 5

<210> 47
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 47
 Gly Gly Gln Lys Arg Arg Leu
 1 5

<210> 48
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 48
 His Glu Gln Lys Arg Arg Ala
 1 5

<210> 49
 <211> 7
 <212> PRT

<213> Homo sapiens

<400> 49

Gly Gly Ala Lys Arg Arg Leu
1 5

<210> 50

<211> 7

<212> PRT

<213> Homo sapiens

<400> 50

His Glu Gln Lys Arg Arg Ser
1 5

<210> 51

<211> 7

<212> PRT

<213> Homo sapiens

<400> 51

Gly Gly Lys Lys Arg Arg Leu
1 5

<210> 52

<211> 7

<212> PRT

<213> Homo sapiens

<400> 52

Gly Gly His Lys Arg Arg Leu
1 5

<210> 53

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> 1

<223> Xaa = Boc (t-butoxy carbonyl)

<221> VARIANT

<222> 5

<223> Xaa = AMC (aminomethylcoumarin)

<400> 53

Xaa Phe Ser Arg Xaa
1 5

<210> 54

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT
 <222> 1
 <223> Xaa = Boc (t-butoxy carbonyl)

<221> VARIANT
 <222> 5
 <223> Xaa = AMC (aminomethylcoumarin)

<400> 54
 Xaa Gln Gly Arg Xaa
 1 5

<210> 55
 <211> 5
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = H (hydrogen)

<221> VARIANT
 <222> 5
 <223> Xaa = AMC (aminomethylcoumarin)

<400> 55
 Xaa Pro Phe Arg Xaa
 1 5

<210> 56
 <211> 5
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Boc (t-butoxy carbonyl)

<221> VARIANT
 <222> 5
 <223> Xaa = AMC (aminomethylcoumarin)

<400> 56
 Xaa Val Pro Arg Xaa
 1 5

<210> 57
 <211> 5
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = H-D (free amine without protecting group)

<221> VARIANT
 <222> 5
 <223> Xaa = AMC (aminomethylcoumarin)

<400> 57
 Xaa Val Leu Lys Xaa
 1 5

<210> 58
 <211> 5
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Tos (4-Toluenesulphonyl)

<221> VARIANT
 <222> 5
 <223> Xaa = AMC (aminomethylcoumarin)

<400> 58
 Xaa Gly Pro Arg Xaa
 1 5

<210> 59
 <211> 5
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Tos (4-Toluenesulphonyl)

<221> VARIANT
 <222> 5
 <223> Xaa = AMC (aminomethylcoumarin)

<400> 59
 Xaa Gly Pro Lys Xaa
 1 5

<210> 60
 <211> 5
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> 1
 <223> Xaa = Z (carbobenzyloxy)

<221> VARIANT
 <222> 5

<223> Xaa = AMC (aminomethylcoumarin)

<400> 60

Xaa Leu Leu Arg Xaa

1

5

<210> 61

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> 1

<223> Xaa = Z (carbobenzyloxy)

<221> VARIANT

<222> 5

<223> Xaa = AMC (aminomethylcoumarin)

<400> 61

Xaa Val Val Arg Xaa

1

5

<210> 62

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> 1

<223> Xaa = Z (carbobenzyloxy)

<221> VARIANT

<222> 5

<223> Xaa = AMC (aminomethylcoumarin)

<400> 62

Xaa Ala Arg Arg Xaa

1

5

<210> 63

<211> 6

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> 1

<223> Xaa = H (hydrogen)

<221> VARIANT

<222> 5

<223> Xaa = AMC (aminomethylcoumarin)

<400> 63

Xaa Arg Gln Arg Arg Xaa
1 5

<210> 64
<211> 10
<212> PRT
<213> Homo sapiens

<220>
<221> VARIANT
<222> 1
<223> Xaa = Mu (morphourea)

<221> VARIANT
<222> 10
<223> Xaa = AMC (aminomethylcoumarin)

<400> 64
Xaa Ala Pro Val Leu Ile Leu Ser Arg Xaa
1 5 10

<210> 65
<211> 9
<212> PRT
<213> Homo sapiens

<220>
<221> VARIANT
<222> 1
<223> Xaa = Mu (morphourea)

<221> VARIANT
<222> 9
<223> Xaa = AMC (aminomethylcoumarin)

<400> 65
Xaa Val Pro Leu Ile Gln Ser Arg Xaa
1 5

<210> 66
<211> 8
<212> PRT
<213> Homo sapiens

<400> 66
Gly His Glu Gln Lys Arg Arg Leu
1 5

<210> 67
<211> 8
<212> PRT
<213> Homo sapiens

<400> 67
Gly Gly Gly Lys Ala Arg Arg Leu
1 5

<210> 68
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 68
 Gly Gly Gly Lys Ala His Arg Leu
 1 5

<210> 69
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 69
 Gly Pro Ala His Gln Arg Arg Leu
 1 5

<210> 70
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 70
 Gly Ser Lys Gly His Phe Arg Leu
 1 5

<210> 71
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 71
 Gly Ser Lys Gly His Arg Arg Leu
 1 5

<210> 72
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 72
 Gly Lys Asp Val Ser Arg Arg Leu
 1 5

<210> 73
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 73
 Gly Ser Gln Asn Gln Arg Arg Leu
 1 5

<210> 74
 <211> 8
 <212> PRT

<213> Homo sapiens

<400> 74

Gly Ser Tyr Pro Ser Arg Arg Leu
1 5

<210> 75

<211> 8

<212> PRT

<213> Homo sapiens

<400> 75

Gly Ser Tyr Pro Ser Ser Arg Leu
1 5

<210> 76

<211> 8

<212> PRT

<213> Homo sapiens

<400> 76

Gly His Glu Gln Lys Gly Arg Leu
1 5

<210> 77

<211> 8

<212> PRT

<213> Homo sapiens

<400> 77

Gly Ser Asn Thr Glu Arg Arg Leu
1 5

<210> 78

<211> 8

<212> PRT

<213> Homo sapiens

<400> 78

Gly Ser Tyr Glu Glu Arg Arg Leu
1 5

<210> 79

<211> 8

<212> PRT

<213> Homo sapiens

<400> 79

Gly Lys Asp Val Ser Gly Arg Leu
1 5

<210> 80

<211> 8

<212> PRT

<213> Homo sapiens

<400> 80

Gly Ser Asn Thr Glu Lys Arg Leu
1 5

<210> 81
<211> 8
<212> PRT
<213> Homo sapiens

<400> 81
Gly Ser Lys Gly His Phe His Leu
1 5

<210> 82
<211> 8
<212> PRT
<213> Homo sapiens

<400> 82
Gly Ser Gln Asn Gln Val Arg Leu
1 5

<210> 83
<211> 8
<212> PRT
<213> Homo sapiens

<400> 83
Gly Pro Leu Ile Leu Ser Arg Leu
1 5

<210> 84
<211> 8
<212> PRT
<213> Homo sapiens

<400> 84
Gly Ser Tyr Glu Glu Arg His Leu
1 5

<210> 85
<211> 8
<212> PRT
<213> Homo sapiens

<400> 85
Gly Lys Asp Val Ser Gly His Leu
1 5

<210> 86
<211> 8
<212> PRT
<213> Homo sapiens

<400> 86
Gly Gly Gly Lys Ala His His Leu
1 5

<210> 87
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 87
 Gly Ser Asn Thr Glu Lys His Leu
 1 5

<210> 88
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 88
 Gly Pro Ala His Gln Asp Arg Leu
 1 5

<210> 89
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 89
 Gly His Glu Gln Lys Gly His Leu
 1 5

<210> 90
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 90
 Gly Pro Ala His Gln Asp His Leu
 1 5

<210> 91
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 91
 Gly Ser Tyr Pro Ser Ser His Leu
 1 5

<210> 92
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 92
 Gly Ser Gln Asn Gln Val His Leu
 1 5

<210> 93
 <211> 8
 <212> PRT

<213> Homo sapiens

<400> 93

Gly His Ala Gln Lys Arg Arg Leu
1 5

<210> 94

<211> 7

<212> PRT

<213> Homo sapiens

<400> 94

Gly Gly Lys Ser Arg Arg Leu
1 5

<210> 95

<211> 8

<212> PRT

<213> Homo sapiens

<400> 95

Gly His Glu Ala Lys Arg Arg Leu
1 5

<210> 96

<211> 7

<212> PRT

<213> Homo sapiens

<400> 96

Gly Gly Gln Lys Arg Arg Leu
1 5

<210> 97

<211> 8

<212> PRT

<213> Homo sapiens

<400> 97

Gly His Glu Gln Lys Arg Arg Ala
1 5

<210> 98

<211> 7

<212> PRT

<213> Homo sapiens

<400> 98

Gly Gly Ala Lys Arg Arg Leu
1 5

<210> 99

<211> 8

<212> PRT

<213> Homo sapiens

<400> 99

Gly His Glu Gln Lys Arg Arg Ser
1 5

<210> 100
<211> 7
<212> PRT
<213> Homo sapiens

<400> 100
Gly Gly Lys Lys Arg Arg Leu
1 5

<210> 101
<211> 7
<212> PRT
<213> Homo sapiens

<400> 101
Gly Gly His Lys Arg Arg Leu
1 5

<210> 102
<211> 7
<212> PRT
<213> Homo sapiens

<400> 102
Gly Gly Lys Ala Phe Arg Leu
1 5

<210> 103
<211> 8
<212> PRT
<213> Homo sapiens

<400> 103
Gly Ala Glu Gln Lys Arg Arg Leu
1 5

<210> 104
<211> 7
<212> PRT
<213> Homo sapiens

<400> 104
Gly Gly Lys Ala Gln Arg Leu
1 5

<210> 105
<211> 7
<212> PRT
<213> Homo sapiens

<400> 105
Gly Gly Lys Ala Arg Arg Leu
1 5

<210> 106
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 106
 Gly Gly Lys Gln Arg Arg Leu
 1 5

<210> 107
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 107
 Gly Gly Lys His Arg Arg Leu
 1 5

<210> 108
 <211> 8
 <212> PRT
 <213> Homo sapiens

<400> 108
 Gly His Glu Gln Ala Arg Arg Leu
 1 5

<210> 109
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 109
 Gly Gly Lys Ala Lys Arg Leu
 1 5

<210> 110
 <211> 8
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> 8
 <223> Xaa = dL which is an isomer of Leu

<400> 110
 Gly His Glu Gln Lys Arg Arg Xaa
 1 5

<210> 111
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 111
 Gly Gly Lys Ala Arg Arg Ser

1

<211> 7
 <212> PRT
 <213> Homo sapiens

<400> 118
 Gly Gly Lys Ala Arg Asn Leu
 1 5

<210> 119
 <211> 7
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> 5
 <223> Xaa = dR which is an isomer of Arg

<400> 119
 Gly Gly Lys Ala Xaa Arg Leu
 1 5

<210> 120
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 120
 Gly Gly Lys Ala Lys Lys Leu
 1 5

<210> 121
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 121
 Gly Gly Lys Ala His Lys Leu
 1 5

<210> 122
 <211> 7
 <212> PRT
 <213> Homo sapiens

<220>
 <221> VARIANT
 <222> 6
 <223> Xaa = dR which is an isomer of Arg

<400> 122
 Gly Gly Lys Ala Arg Xaa Leu
 1 5

<210> 123
 <211> 7
 <212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> 5, 6

<223> Xaa = dR which is an isomer of Arg

<400> 123

Gly Gly Lys Ala Xaa Xaa Leu

1

5

<210> 124

<211> 5

<212> PRT

<213> Homo sapiens

<400> 124

Ala Gln Lys Arg Arg

1

5

<210> 125

<211> 5

<212> PRT

<213> Homo sapiens

<400> 125

Gly Lys Ser Arg Arg

1

5

<210> 126

<211> 5

<212> PRT

<213> Homo sapiens

<400> 126

Glu Gln Lys Arg Arg

1

5

<210> 127

<211> 5

<212> PRT

<213> Homo sapiens

<400> 127

Glu Ala Lys Arg Arg

1

5

<210> 128

<211> 5

<212> PRT

<213> Homo sapiens

<400> 128

Gly Gln Lys Arg Arg

1

5

<210> 129

<211> 5
 <212> PRT
 <213> Homo sapiens

<400> 129
 Gly Ala Lys Arg Arg
 1 5

<210> 130
 <211> 5
 <212> PRT
 <213> Homo sapiens

<400> 130
 Gly Lys Lys Arg Arg
 1 5

<210> 131
 <211> 5
 <212> PRT
 <213> Homo sapiens

<400> 131
 Gly His Lys Arg Arg
 1 5

<210> 132
 <211> 5
 <212> PRT
 <213> Homo sapiens

<400> 132
 Gly Lys Ala Phe Arg
 1 5

<210> 133
 <211> 5
 <212> PRT
 <213> Homo sapiens

<400> 133
 Glu Lys Ala Gln Arg
 1 5

<210> 134
 <211> 5
 <212> PRT
 <213> Homo sapiens

<400> 134
 Glu Lys Ala Arg Arg
 1 5

<210> 135
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 135

Gly Gly Lys Ala Arg Arg Leu
1 5

Express Mail Label No. EL 933049160 US
Docket No. 57109 (71699)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: S. Denmeade, et al.
U.S.S.N.: 09/627,600 Group: 1655
FILED: July 28, 2000 Confirmation No.: 3631
FOR: ACTIVATION OF PEPTIDE PRODRUGS BY (HK2)

Box Sequence
Commissioner for Patents
Washington, DC 20231

SIR:

LETTER

Applicants wish to bring to the attention of the Patent Office the following address
change for the Agent.

Agent's old correspondence address:

Fish & Richardson, P.C.
45 Rockefeller Plaza
Suite 2800
New York, New York
Telephone: (212) 765-5070
Facsimile: (212) 258-2291

Agent's new correspondence address:

EDWARDS & ANGELL, LLP
Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
P.O. Box 9169
Boston, Massachusetts 02209
Telephone: (617) 439-4444
Facsimile: (617) 439-4170

Applicants kindly ask that this address change for Agent be made of record in the above-identified application.

Please charge any fees that may be due in connection with this matter to Deposit Account 04-1105.

Please contact the undersigned attorney if any additional information is needed.

Respectfully submitted,



Dianne M. Rees, Ph.D. (Reg. No. 45,281)
Intellectual Property Group of
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
(617) 439-4444

Customer No. 21874

Express Mail Label No. EL 933049160 US
Attorney Docket No. 57109 (71699)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): S. Denmeade, et al.

U.S.S.N.: 09/627,600

FILED: July 28, 2000

FOR: ACTIVATION OF PEPTIDE PRODRUGS BY (HK2)

Box Sequence
Commissioner for Patents
Washington, D.C. 20231

.....
Sir:


ASSOCIATE POWER OF ATTORNEY (37 CFR 1.34)

Please recognize the following as an Associate Agent in this case:

Dianne Rees, Reg. No. 45,281.

Respectfully submitted,

Date: 18 July 2002



Peter F. Corless (Reg. No. 33,860)
EDWARDS & ANGELL, LLP
P.O. BOX 9169
Boston, Massachusetts 02209
(617-439-4444)

Customer No: 21874